Full central neurokinin-1 receptor blockade is required for efficacy in depression: Evidence from orvepitant clinical studies

by Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E.A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., Fava, M.
Published 2014

First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

by Teneggi, V, Novotny-Diermayr, V, Lee, LH, Yasin, M, Yeo, P, Ethirajulu, K, Gan, SBH, Blanchard, SE, Nellore, R, Umrani, DN, Gomeni, R, Teck, DLW, Li, G, Lu, QS, Cao, Y, Matter, A
Published 2021